Antonio D’Alessio, Medical Oncologist and PhD student at Imperial College London, shared on X:
“Do you remember adjuvant cell therapy for HCC? At ASCOGI25 the NINE year (!) follow-up was presented:
maintained significant RFS benefit
reduction in cancer-specific death
increase in CD8+ memory T cells
Adjuvant therapy for HCC: not everything is lost ?”
